CS 3005
Alternative Names: CS3005Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator CStone Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Australia (PO)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in China
- 17 Feb 2021 CStone Pharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (PO) (NCT04233060)